You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 273 No. 7, February 15, 1995 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (12)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Genetic Origins of Neoplasia

Arnold J. Levine, PhD

JAMA. 1995;273(7):592.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The last 15 years have witnessed a conceptual breakthrough in our understanding of the molecular and genetic basis of the origins of neoplasia in humans. This happened methodically, experiment by experiment, with no one observation yielding the entire picture. Over time, a large number of observations slowly came together, and, for that reason, we often do not give enough credit to the science, or the scientists, for this remarkable achievement.

Mutations in three broad categories of genes have been shown to contribute to the origins and progression of neoplasia in humans: the oncogenes, the tumor suppressor genes, and the mutator genes. Almost 100 different oncogenes have been identified in animals and humans and shown to contain mutations in a wide variety of tumors. Most of these oncogenes were discovered with the use of retro viruses that insert adjacent to an oncogene and activate it or capture the oncogene in a . . . [Full Text PDF of this Article]


Author Affiliations

From the Department of Molecular Biology and the Lewis Thomas Laboratory, Princeton University, Princeton, NJ. Research in the laboratory of Dr Levine has been sponsored by the National Cancer Institute, Onyx Pharmaceuticals, and Imclone Systems. He has stock options in Onyx Pharmaceuticals and Imclone Systems.


Footnotes

Correspondence to Department of Molecular Biology, Princeton University, Washington Road, Room 119, Princeton, NJ 08544 (Dr Levine).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.